Survival analysis of extrahepatic cholangiocarcinoma based on surveillance, epidemiology, and end results database

Backgrounds/Aims Cholangiocarcinoma (CCA) can be classified as intrahepatic CCA or extrahepatic CCA (eCCA). We intended to analyze and reports the survival outcomes for eCCA. Methods Surveillance, epidemiology, and end results (SEER) registry, site recode C24.0, was used to select cases of eCCA from 2000 to 2018. Patients with incomplete data or ages <18 years were excluded. Results Male (52.69%) and White race (77.99%) predominated. Compared with 2000–2006, survival increased in 2013 (adjusted hazard ratio [HRadj]: 0.68, 95% confidence interval [CI] 0.58–0.70; p < 0.01). Surgery with chemoradiotherapy (HRadj: 0.69, 95% CI 0.60–0.7; p < 0.01) and surgery with chemotherapy (HRadj: 0.72, 95% CI 0.62–0.83; p < 0.01) improved survival over surgery alone. Compared with surgery without lymph node (LN) removal, surgery of four or more regional LN reduced the risk of death by 58% (HRadj: 0.42, 95% CI 0.36–0.51; p < 0.01). Compared with patients without surgery, patients who underwent bile duct excision (HRadj: 0.82, 95% CI 0.72–0.94; p < 0.01), simple or extended lobectomy (HRadj: 0.85, 95% CI 0.75–0.95; p = 0.009), and hepatectomy (HRadj: 0.80, 95% CI 0.72–0.88; p < 0.01) significantly improved survival. Patients with distal CCA had a 17% higher survival than perihilar CCA (HRadj: 0.83, 95% CI 0.74–0.92; p < 0.01) and LN dissection was equally beneficial for both subgroups (p < 0.01). Conclusions Surgery with chemoradiotherapy has a proven increase in the 5-year survival of the eCCA. LN resection, bile duct excision, lobectomy, and hepatectomy have better outcomes.

[1]  Hassam Ali,et al.  Changing incidence and survival of intrahepatic cholangiocarcinoma based on Surveillance, Epidemiology, and End Results Database (2000-2017) , 2022, Annals of hepato-biliary-pancreatic surgery.

[2]  Yunbing Wang,et al.  Postoperative survival of extrahepatic and intrahepatic cholangiocarcinoma after surgery: a population-based cohort , 2022, BMJ Open.

[3]  Yi Gong,et al.  Evaluation of Four Lymph Node Classifications for the Prediction of Survival in Hilar Cholangiocarcinoma , 2022, Journal of Gastrointestinal Surgery.

[4]  Hassam Ali,et al.  Pancreatic cancer incidence trends in the United States from 2000-2017: Analysis of Surveillance, Epidemiology and End Results (SEER) database , 2021, F1000Research.

[5]  Peng Liao,et al.  Analysis of metastasis and survival between extrahepatic and intrahepatic cholangiocarcinoma , 2021, Medicine.

[6]  B. Graubard,et al.  Hepatocellular Carcinoma Survival by Etiology: A SEER‐Medicare Database Analysis , 2020, Hepatology communications.

[7]  Anas M. Saad,et al.  Epidemiology of Cholangiocarcinoma; United States Incidence and Mortality Trends. , 2020, Clinics and research in hepatology and gastroenterology.

[8]  Hongwei Wang,et al.  Development and external validation of a nomogram for predicting the effect of tumor size on survival of patients with perihilar cholangiocarcinoma , 2020, BMC cancer.

[9]  J. Raftery,et al.  Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study. , 2019, The Lancet. Oncology.

[10]  A. Forner,et al.  Clinical presentation, diagnosis and staging of cholangiocarcinoma , 2019, Liver international : official journal of the International Association for the Study of the Liver.

[11]  HaoYang Zhu,et al.  Racial disparities in the survival time of patients with hepatocellular carcinoma and intrahepatic cholangiocarcinoma between Chinese patients and patients of other racial groups: A population-based study from 2004 to 2013 , 2018, Oncology letters.

[12]  G. Poston,et al.  Meta‐analysis of prognostic factors for overall survival in patients with resected hilar cholangiocarcinoma , 2018, The British journal of surgery.

[13]  M. Nagino,et al.  Surgical resection for Bismuth type IV perihilar cholangiocarcinoma , 2018, The British journal of surgery.

[14]  T. Pawlik,et al.  Performance of prognostic scores and staging systems in predicting long‐term survival outcomes after surgery for intrahepatic cholangiocarcinoma , 2017, Journal of surgical oncology.

[15]  S. Stewart,et al.  Racial/ethnic disparities in hepatocellular carcinoma treatment and survival in California, 1988-2012 , 2016, World journal of gastroenterology.

[16]  Han Zhang,et al.  Intrahepatic cholangiocarcinoma: Epidemiology, risk factors, diagnosis and surgical management. , 2016, Cancer letters.

[17]  L. Roberts,et al.  Biliary tract cancers: epidemiology, molecular pathogenesis and genetic risk associations. , 2016, Chinese clinical oncology.

[18]  T. Pawlik,et al.  Patterns and prognostic value of lymph node dissection for resected perihilar cholangiocarcinoma , 2016, Journal of gastroenterology and hepatology.

[19]  G. Gores,et al.  An Optimized Set of Fluorescence In Situ Hybridization Probes for Detection of Pancreatobiliary Tract Cancer in Cytology Brush Samples. , 2015, Gastroenterology.

[20]  D. Abbott,et al.  Adjuvant Chemotherapy and Radiation Therapy is Associated with Improved Survival for Patients with Extrahepatic Cholangiocarcinoma , 2015, Annals of Surgical Oncology.

[21]  Jung Chul Kim,et al.  The prognostic factors for survival after curative resection of distal cholangiocarcinoma: perineural invasion and lymphovascular invasion , 2014, Surgery Today.

[22]  H. Zhang,et al.  Loss of MTSS1 Expression is an Independent Prognostic Factor for Hilar Cholangiocarcinoma , 2013, Pathology & Oncology Research.

[23]  W. Kim,et al.  Excellent quality of life after liver transplantation for patients with perihilar cholangiocarcinoma who have undergone neoadjuvant chemoradiation , 2013, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[24]  T. Pawlik,et al.  Management of perihilar cholangiocarcinoma in the era of multimodal therapy , 2012, Expert review of gastroenterology & hepatology.

[25]  G. Gores,et al.  Clinical diagnosis and staging of cholangiocarcinoma , 2011, Nature Reviews Gastroenterology &Hepatology.

[26]  H. El‐Serag,et al.  Risk factors for cholangiocarcinoma , 2011, Hepatology.

[27]  G. Kaplan,et al.  Incidence of primary sclerosing cholangitis: A systematic review and meta‐analysis , 2011, Hepatology.

[28]  D. Cunningham,et al.  Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. , 2010, The New England journal of medicine.

[29]  C. Pairojkul,et al.  Cholangiocarcinoma: lessons from Thailand , 2008, Current opinion in gastroenterology.

[30]  T. O'Brien,et al.  Impact of classification of hilar cholangiocarcinomas (Klatskin tumors) on the incidence of intra- and extrahepatic cholangiocarcinoma in the United States. , 2006, Journal of the National Cancer Institute.

[31]  Jin‐Young Jang,et al.  Actual Long-term Outcome of Extrahepatic Bile Duct Cancer After Surgical Resection , 2005, Annals of surgery.

[32]  H. El‐Serag,et al.  The epidemiology of cholangiocarcinoma. , 2004, Seminars in liver disease.

[33]  S. Taylor-Robinson,et al.  Risk Factors for Intrahepatic and Extrahepatic Cholangiocarcinoma: a systematic review and meta-analysis. , 2019, Journal of hepatology.

[34]  P. Tushar,et al.   Intrahepatic, perihilar and distal cholangiocarcinoma: Management and outcomes. , 2017, Annals of hepatology.